https://journaljcti.com/index.php/JCTI <p style="text-align: justify;"><strong>Journal of Cancer and Tumor International (ISSN: 2454-7360)</strong>&nbsp;aims to publish high quality papers (<a href="/index.php/JCTI/general-guideline-for-authors">Click here for Types of paper</a>) in all areas of&nbsp;‘Cancer and&nbsp;Tumor research’. By not excluding papers based on novelty, this journal facilitates the research and wishes to publish papers as long as they are technically correct and scientifically motivated. The journal also encourages the submission of useful reports of negative results. This is a quality controlled, OPEN peer-reviewed, open-access INTERNATIONAL journal.</p> en-US [email protected] (Journal of Cancer and Tumor International) [email protected] (Journal of Cancer and Tumor International) Thu, 28 May 2026 13:53:55 +0000 OJS 3.3.0.21 http://blogs.law.harvard.edu/tech/rss 60 https://journaljcti.com/index.php/JCTI/article/view/357 <p><strong>Background:</strong> Breast cancer is the leading malignancy among women in Cameroon, yet national decision-making still relies heavily on international estimates, isolated hospital series and incompletely documented registries. This limitation weakens the interpretation of incidence, prevalence, mortality, survival and treatment indicators, and may delay evidence-based cancer control planning. This systematic review and meta-analysis aimed to synthesize the published evidence on breast cancer in Cameroon, quantify key epidemiological and clinical outcomes, and identify methodological gaps that compromise national comparability.</p> <p><strong>Methods:</strong> We conducted a systematic review and meta-analysis of observational studies reporting breast cancer data from Cameroon between 1 January 2000 and 30 April 2025. MEDLINE/PubMed, EMBASE, Google Scholar and the WHO Global Health Library were searched without language restriction. Eligible designs included cohort, cross-sectional, case-control and retrospective hospital-based studies reporting at least one of the following outcomes: prevalence, incidence, mortality, five-year survival, clinical stage, histological profile, immunohistochemistry or treatment patterns. Study quality was assessed using the Newcastle-Ottawa Scale. Pooled proportions were estimated using random-effects models after Freeman-Tukey double-arcsine transformation, with heterogeneity quantified using Cochran's Q and I2 statistics.</p> <p><strong>Results:</strong> Fifty-six studies including 41,494 breast cancer patients were retained. The mean age was 45.97 ± 5.53 years, and women represented 96.3% of reported cases. Breast cancer accounted for a pooled 32% of female cancers (95% confidence interval [CI]: 14%-57%; I2=97%). The pooled mortality proportion was 72% (95% CI: 6%-99%; I²=97.7%), while pooled five-year overall survival was 36% (95% CI: 26%-47%; I2=92.2%). Most patients were diagnosed at advanced stages, with stage III and IV disease accounting for the majority of reported cases. Ductal carcinoma was the dominant histology. Hormone receptor positivity was frequent (estrogen receptor: 82%; progesterone receptor: 56%), whereas HER2 overexpression was less frequently reported (14%). Treatment reporting was incomplete: chemotherapy and radiotherapy were commonly documented, but endocrine therapy and palliative care were substantially underreported.</p> <p><strong>Conclusion:</strong> Published breast cancer research from Cameroon indicates a severe clinical burden marked by late diagnosis, high mortality and poor five-year survival. However, the extreme heterogeneity and inconsistent reporting across studies show that the country's breast cancer evidence base remains structurally fragile. Standardized cancer registration, harmonized minimum datasets, routine immunohistochemistry, active survival follow-up and transparent treatment documentation are urgently needed to support effective breast cancer control in Cameroon.</p> Jean Paul Engbang, Ambroise Ntama, Henry Essome, Esther Dina Bell Mbassi, Charlotte Nguefack Tchente, Zacharie Sando Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://journaljcti.com/index.php/JCTI/article/view/357 Thu, 28 May 2026 00:00:00 +0000 https://journaljcti.com/index.php/JCTI/article/view/358 <p><strong>Background: </strong>Glioblastoma is the most aggressive primary malignant brain tumor in adults and is associated with poor prognosis despite advances in surgical and adjuvant therapies. Extent of resection (EOR) has emerged as a critical prognostic factor influencing survival outcomes; however, the optimal degree of tumor removal and its relationship with clinical and pathological characteristics remain controversial.</p> <p><strong>Objective: </strong>To systematically evaluate the impact of extent of resection on overall survival (OS) and progression-free survival (PFS) in patients with glioblastoma and to assess associated clinical and pathological correlates.</p> <p><strong>Methods: </strong>A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, Scopus, Web of Science, and Cochrane Library databases were searched for eligible studies published from 2000 to 2026. Studies comparing survival outcomes according to extent of resection, including gross total resection (GTR), subtotal resection (STR), supramarginal resection (SMR), and biopsy, were included. Data extraction and quality assessment were independently performed by two reviewers. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models, and heterogeneity was assessed using the I² statistic.</p> <p><strong>Results: </strong>A total of [number] studies involving [number] patients with glioblastoma were included. Compared with STR or biopsy, GTR was significantly associated with improved OS (pooled).</p> Osman Suliman, Sara Altom, Nada Abulaban, Rana Abdelmagid, Riham Abdelmagid, Ahmed Abdelmagid Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://journaljcti.com/index.php/JCTI/article/view/358 Fri, 29 May 2026 00:00:00 +0000